E-LIB Suche - Ergebnisse für: Liberati, Anna Marina

1

Local radiotherapy and measurable residual disease-driven i..:

Pulsoni, Alessandro ; Ferrero, Simone ; Tosti, Maria Elena...
The Lancet Haematology. 11 (2024) 7 - p. e499-e509 , 2024

Link: https://doi.org/10.1016/..

2

IELSG30 phase 2 trial: intravenous and intrathecal CNS prop..:

Conconi, Annarita ; Chiappella, Annalisa ; Ferreri, Andrés J. M....
Blood Advances. 8 (2024) 6 - p. 1541-1549 , 2024

Link: https://doi.org/10.1182/..

3

Additional copies of 1q negatively impact the outcome of mu..:

D'Agostino, Mattia ; Rota-Scalabrini, Delia ; Belotti, Angelo...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

4

Bendamustine and rituximab as first-line treatment for symp..:

Iannitto, Emilio ; Ferrero, Simone ; Bommier, Côme...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

5

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGI..:

D'agostino, Mattia ; Bringhen, Sara ; Giuliani, Nicola...
HemaSphere. 7 (2023) S3 - p. e993869a , 2023

Link: https://doi.org/10.1097/..

6

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Pa..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S433-S434 , 2023

Link: https://doi.org/10.1016/..

7

Tafasitamab for patients with relapsed or refractory diffus..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Haematologica. 109 (2023) 2 - p. 553-566 , 2023

Link: https://doi.org/10.3324/..

8

Role of Rituximab Addition to First-line Chemotherapy Regim..:

Gotti, Manuel ; Sciarra, Roberta ; Pulsoni, Alessandro...
HemaSphere. 7 (2023) 4 - p. e837 , 2023

Link: https://doi.org/10.1097/..

9

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitam..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S206 , 2023

Link: https://doi.org/10.1016/..

10

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALI..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
HemaSphere. 7 (2023) S3 - p. e7389505 , 2023

Link: https://doi.org/10.1097/..

11

High rate of durable responses with undetectable minimal re..:

Mauro, Francesca R. ; Starza, Irene Della ; Messina, Monica...
Haematologica. 108 (2023) 8 - p. 2091-2100 , 2023

Link: https://doi.org/10.3324/..

12

Treating relapsed/refractory mature T- and NK-cell neoplasm..:

Bachy, Emmanuel ; Savage, Kerry J. ; Huang, Huiqiang...
Blood Advances. 7 (2023) 16 - p. 4435-4447 , 2023

Link: https://doi.org/10.1182/..

13

Brentuximab Vedotin and Bendamustine Produce Long-Term Clin..:

Moretti, Marina ; Liberati, Anna Marina ; Rigacci, Luigi...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) 3 - p. 198-204 , 2022

Link: https://doi.org/10.1016/..

14

OAB-011: Predictors of unsustained negativity in minimal re..:

D'Agostino, Mattia ; Oliva, Stefania ; Rota-Scalabrini, Delia...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S6-S7 , 2022

Link: https://doi.org/10.1016/..

15

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Pati..:

Duell, Johannes ; Jurczak, Wojciech ; Liberati, Anna Marina...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S375 , 2022

Link: https://doi.org/10.1016/..